Donate today to support women in science at Burnet and their work to unlock the vaginal microbiome and reduce risk of HIV infection and preterm birth for women around the world.
Improving the health of vulnerable communities and changing lives is at the heart of what we do and who we are.
There are 35.3 million people worldwide infected with HIV, the virus that causes AIDS. Although drugs now exist that allow HIV patients to live longer, healthier lives, the cost of pre-treatment testing has limited access to drugs among patients in resource-poor countries. In response, Kieran Cashin and colleagues from the Gorry laboratory have created a free online computer program that mimics pre-treatment tests. We hope that this program will aid access to anti-HIV drugs, particularly in developing countries burdened most by the HIV pandemic. This tool has been specifically developed for subtype C HIV-1, which is the predominant subtype in the HIV-1 pandemic.
“CoRSeqV3-C is a HIV-1 subtype C specific V3 sequence-based coreceptor usage prediction algorithm. Refer to “Cashin, K et al., Retrovirology 2013 10:24” for a description of the CoRSeqV3-C development process and prediction criteria.
An updated version of CoRSeqV3-C (renamed PhenoSeq-C) can be found here.
For any general enquiries relating to this facility, please contact:
Facilities Officer
To create and translate knowledge into better health, so no-one is left behind.
85 Commercial Road, Melbourne
VIC, 3004, Australia
Receive updates and IMPACT magazine.
Copyright © 2023 Burnet Institute. ABN: 49 007 349 984
This website was developed with the generous support of a donor.
Burnet Institute (Australia) is located on the traditional land of the Boon Wurrung people and we offer our respects to their Elders past and present.
We recognise and respect the continuation of cultural, spiritual and educational practices of Aboriginal and Torres Strait Islander peoples of this land.
